# HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial

> **NCT04135690** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 60 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** Hepatic arterial infusion chemotherapy
- **DRUG:** Toripalimab
- **DRUG:** Sorafenib
- **DRUG:** systemic treatment

## Key facts

- **NCT ID:** NCT04135690
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-20
- **Primary completion:** 2023-12-20
- **Final completion:** 2023-12-20
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04135690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04135690, "HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04135690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*